Atopic Dermatitis the focus in 2018
Realm Therapeutics (RLM) is developing a pipeline of novel topical treatments principally to treat highly prevalent dermatology indications using its proprietary hypochlorous acid (HOCl) technology, which has shown immunomodulatory properties coupled with a potentially favourable safety profile. FY’17 highlights included entry of lead program PR022 a topical gel to treat Atopic Dermatitis into FDA Phase II study due to provide headline data in Q3’18.RLM is on track to file an Investigational New Drug application (IND) for its second topical dermatology indication for new program RLM023, in Acne Vulgaris in Q418 with a view to a Phase II Proof of Concept study start in Q1’19. A third dermatology indication is being evaluated in Psoriasis, the most prevalent auto-immune disorder in the US with around 7.5m sufferers according to the American Academy of Dermatology, aiming to providing a safer and efficacious treatment alternative to potent first line therapies.
The company initiated a Phase II study for its lead candidate PR022 a topical gel for treating mild-to-moderate Atopic Dermatitis in December, with data anticipated in Q318. Previous preclinical studies demonstrated early promise of its immunomodulatory properties and efficacy alongside good tolerability.
RLM remains on the front foot: advancing its dermatology pipeline and is currently evaluating a third topical dermatology indication in Psoriasis. Post results our valuation of RLM is £79m, equating to 68p / share. As such we continue to regard RLM’s equity as offering an attractive entry point into a well-funded, clinical stage biotech pipeline with little value ascribed to an active pipeline.
AstraZeneca is a holding company. Through its subsidiaries, Co. operates as a biopharmaceutical company engaged in discovering, developing, manufacturing and commercializing its pipeline of small molecule and biologic prescription medicines, including targeted business development through collaboration, in-licensing and acquisitions. Co. is focused on three main therapy areas: Oncology, Cardiovascular and Metabolic Diseases, and Respiratory. Co. is also selectively active in autoimmunity, infection and neuroscience. In addition, Co. works across small molecules, oligonucleotides and other drug platforms, as well as biologic medicines.
Novartis is a multinational healthcare group based in Switzerland. Co. provides healthcare solutions that address the evolving needs of patients and societies worldwide. Co.'s broad portfolio includes innovative medicines, eye care products and cost-saving generic pharmaceuticals. Co.'s operations are organized along three operating divisions: Innovative Medicines Division; Sandoz Division; and Alcon Division. Co.'s operations are supported by the Novartis Institutes for BioMedical Research and Novartis Business Services.
Pfizer is a research-based biopharmaceutical company. The company is engaged in discovering, developing, manufacturing and distributing of healthcare products, including medicines and vaccines. The company manages its commercial operations through three businesses: Pfizer Biopharmaceuticals Group, which includes Oncology, Inflammation and Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine business units, as well as a hospital business unit; Upjohn, which includes the company's solid oral dose brands such as Lyrica, Lipitor, Norvasc, Celebrex, Viagra, and certain generic medicines; and Consumer Healthcare, which is an over-the-counter medicines business.
Realm Therapeutics is a clinical stage biopharmaceutical company focused on utilizing its proprietary immunomodulatory technology. Co. is engaged in the development of prescription treatments for inflammatory diseases including indications in Dermatology and Ophthalmology. Co. has developed proprietary formulations of its technology for initial application in Atopic Dermatitis (PR022) and Allergic Conjunctivitis (PR013). Co.'s first product, PR022, is a proprietary non-alcohol based, topical gel, which has shown therapeutic effect in pre-clinical models of Atopic Dermatitis. Co.'s second product, PR013, a proprietary topical ophthalmic solution for the treatment of Allergic Conjunctivitis.
Roche Holding is a healthcare company. Co. operates in two Divisions, Pharmaceuticals and Diagnostics. Co.'s pharmaceuticals division is comprised of two business segments Roche Pharmaceuticals and Chugai. Co.'s pharmaceuticals division provides therapies including Cotellic, in combination with Zelboraf for advanced melanoma, and Alecensa for a specific type of lung cancer. Co.'s diagnostics division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. Co.'s diagnostics division provides in vitro diagnostic tests, used by healthcare providers to screen, diagnose and monitor therapies.
Equity Development enables companies to become better understood and supported by investors. Since our launch in 1996 we have consistently focused on helping our clients improve their communication and relationships with both existing and potential shareholders. Our clients have come from a wide variety of sectors and domiciles, are both private and quoted and range in size from micro-cap to $multi-billions. We offer free access to company research notes written by experienced analysts. These notes include detailed forecasts, financial models and a fair value. We host regular Private Investor Forums at which investors have the opportunity to hear company directors present, and to ask questions. These are free to attend. We broadcast live Webinars with company management that include active Q&A. We also make the recordings available online. We arrange face to face meetings between private investors and company management. We are active users of Twitter, commenting daily on company news, share price moves, Directors’ Dealings, Equity Development Research Notes & Events.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.